BioMarin Pharma (BMRN) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioMarin Announces Fourth Quarter and Full Year 2015 Financial Results
February 25, 2016 4:02 PM EST- Full-year 2015 Total BioMarin Revenue Increases 18.8% to $889.9 million Year-over-Year
- Vimizim Net Product Revenue Contributes Over $228 million to 2015 Top-line
- Full-year 2016 Total BioMarin Revenue Guidance of Between $1.05 billion to $1.10 billion
- Company Anticipates Non-GAAP Breakeven or Better in 2017 Under all E.U. Outcomes with Kyndrisa
Financial Highlights ($ in millions, except per share data, unaudited)
  Three Months Ended December 31,  Twelve Months... More